Evidence map›Paper›PMID 15159277›Full record

ArticleBritish journal of pharmacology2004

Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury.

Lavinia M Proctor, Thiruma V Arumugam, Ian Shiels, Robert C Reid, David P Fairlie, Stephen M Taylor

Open access · greenAbstract readComparative Study
In one paragraph

Article in British journal of pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
2.7field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 77 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Beneficial effects ofActa pharmaceutica Sinica. B · 2018
    Article
  15. Article
  16. The Complement System and Preeclampsia.Current hypertension reports · 2017
    Review
  17. Article
  18. From apelin to exercise: emerging therapies for management of hypertension in pregnancy.Hypertension research : official journal of the Japanese Society of Hypertension · 2017
    Review
  19. Review
  20. Tumor necrosis-initiated complement activation stimulates proliferation of medulloblastoma cells.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lavinia M ProctorSchool of Biomedical Sciences, University of Queensland, Brisbane QLD 4072, Australia.
Thiruma V Arumugam
Ian Shiels
Robert C Reid
David P Fairlie
Stephen M Taylor
University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

1. Complement activation is implicated in the pathogenesis of intestinal ischaemia-reperfusion injury (I/R), although the relative importance of individual complement components is unclear. A C3a receptor antagonist N(2)-[(2,2-diphenylethoxy)acetyl]-l-arginine (C3aRA) has been compared with a C5a receptor antagonist (C5aRA), AcF-[OPdChaWR], in a rat model of intestinal I/R. 2. C3aRA (IC(50)=0.15 microm) and C5aRA (IC(50)=0.32 microm) bound selectively to human polymorphonuclear leukocyte (PMN) C3a and C5a receptors, respectively. Effects on circulating neutrophils and blood pressure in the rat were also assessed. 3. Anaesthetised rats, subjected to intestinal ischaemia (30 min) and reperfusion (120 min), were administered intravenously with either (A) the C3aRA (0.1-1.0 mg x kg(-1)); the C5aRA (1.0 mg x kg(-1)); the C3aRA+C5aRA (each 1.0 mg x kg(-1)); or vehicle, 45 min prior, or (B) the C3aRA (1.0 mg x kg(-1)) or vehicle, 120 min prior to reperfusion. 4. The C3aRA and C5aRA, administered 45 min prior to reperfusion, displayed similar efficacies at ameliorating several disease markers (increased oedema, elevated ALT levels and mucosal damage) of rat intestinal I/R. The combination drug treatment did not result in greater injury reduction than either antagonist alone. However, doses of the C3aRA (0.01-10 mg x kg(-1)) caused transient neutropaenia, and the highest dose (10 mg x kg(-1)) also caused a rapid and transient hypertension. 5. The C3aRA (1.0 mg x kg(-1)), delivered 120 min prior to reperfusion to remove the global effect of C3aRA-induced neutrophil sequestration, did not attenuate the markers of intestinal I/R, despite persistent C3aR antagonism at this time. 6. C3aR antagonism does not appear to be responsible for the anti-inflammatory actions of this C3aRA in intestinal I/R in the rat. Instead, C3aRA-mediated global neutrophil tissue sequestration during ischaemia and early reperfusion may account for the protective effects observed.

Indexed as

Disease Models, AnimalAlanine TransaminaseAnimalsAnti-Inflammatory AgentsArginineAustraliaBenzhydryl CompoundsDose-Response Relationship, DrugDrug CombinationsFemaleHumansInjections, IntravenousIntestinal MucosaMembrane ProteinsNeutropeniaNeutrophilsAcPhe(ornithine-Pro-cyclohexylamine-Trp-Arg)Alanine TransaminaseAnti-Inflammatory AgentsArginineBenzhydryl Compoundscomplement C3a receptorDrug CombinationsMembrane ProteinsPeptides, CyclicReceptor, Anaphylatoxin C5aReceptors, ComplementSB 290157

Identifiers

PMID15159277
PMCPMC1575041
OpenAlexW1975140284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.